Evaluation of Immunotoxicity of Sodium Metavanadate Following Drinking Water Exposure in Female B6C3F1/N Mice in a 28-day Study
Rachel Frawley, Victor J. Johnson, Gary R. Burleson, Keith R Shockley, Mark F. Cesta, Greg Travlos, Michelle Cora, Georgia Roberts, Dori Germolec
TOX-106 Vanadium Compounds (Sodium Metavanadate and Vanadyl Sulfate):
Abstract for TOX-106
DOI:
https://doi.org/10.22427/NTP-DATA-500-001-001-000-7
Publication
Abstract
Sodium metavanadate (NaVO₃) is a pentavalent vanadium compound used in the metal industry and in dietary supplements; human exposure occurs through inhalation of fumes and dust, and ingestion of NaVO₃-containing products. The objective of this study was to assess the potential immunotoxicity of NaVO₃. Female B6C3F1/N mice were exposed to 0-500 ppm NaVO₃ in drinking water for 28 days and evaluated for effects on immune cell populations, and innate, cellular-, and humoral-mediated immunity. There was a decreasing trend in body weight (BW) and BW gain in NaVO₃ exposed mice, with a significant (p≤0.05) decrease in BW gain at ≥ 250 ppm, relative to control. Conversely, increasing trends in spleen weights, and an increase (p≤0.05) in the spleen:BW ratio at ≥250 ppm NaVO₃ were observed. NaVO₃ exposure altered antibody production against sheep red blood cells (SRBC). Antibody forming cells (AFC)/10⁶ spleen cells exhibited a decreasing trend, with a significant decrease (p≤0.05) at 500 ppm NaVO₃, concurrent with an increase in percent B-cells. NaVO₃ had no effect on the serum anti-SRBC IgM antibody titers or antibody production against keyhole limpet hemocyanin. Exposure to NaVO₃ decreased the percentage of natural killer (NK) cells at all dose levels (p≤ 0.05), however, the lytic activity of NK cells was not affected. NaVO₃ altered T-cell populations at 500 ppm but had no effect on T-cell proliferative responses or the lytic activity of cytotoxic T-cells. Collectively, these data indicate that NaVO₃ induced alterations in humoral-mediated immunity, specifically the AFC response, with no effect on cell-mediated or innate immunity.
Supplemental Materials
Supplemental Tables
- I01 - Animal Removal Summary (78 KB)
- I02 - Animal Removals (932 KB)
- I03 - Growth Curve (1 MB)
- I03C - Growth Curve (2 MB)
- I04 - Mean Body Weight Summary (307 KB)
- I04G - Mean Body Weight Gain (268 KB)
- I05 - Clinical Observations Summary (100 KB)
- I07 - Mean Water Consumption (295 KB)
- I08 - Mean Test Compound Consumption (237 KB)
- M03 - Peripheral Blood Leukocyte Cell Differential (63 KB)
- M04 - Hematology (59 KB)
- M06 - Spleen Immunophenotyping (83 KB)
- M07 - TDAR SRBC - Spleen AFC (45 KB)
- M08 - Serum IgM Antibody Titers to T - Dependent Antigen Sheep Erythrocytes (32 KB)
- M09 - Serum Antibody Concentrations for the T - Dependent Keyhole Lipet Hemocyanin (KLH) (36 KB)
- M11 - Spleen Cell Proliferative Response to Anti - CD3 Stimulation (33 KB)
- M12 - Cytotoxic T Cell Activity (39 KB)
- M15 - Natural Killer Cell Activity (38 KB)
- M19 - TDAR SRBC - ELISpot (35 KB)
- PA02 – Neoplastic Lesion Summary with Percent Incidence (137 KB)
- PA03 – Non-Neoplastic Lesion Summary with Percent Incidence (127 KB)
- PA05 – Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (137 KB)
- PA06 - Organ Weights Summary (160 KB)
- PA10 → Statistical Analysis of Nonneoplastic Lesiond (134 KB)
- PA14 - Indivdiual Animal Pathology Data (835 KB)
- PA14 - Indivdiual Animal Pathology Data (107 KB)
- PA18 – Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grade (127 KB)
- PA46 - Summary of Gross Pathology (166 KB)